Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the use of dutasteride for treating androgenetic alopecia and reports no new clinical results.

This review describes how dutasteride, a dual 5alpha-reductase inhibitor, has improved outcomes in benign prostatic hyperplasia and is being studied for prostate cancer prevention, without new data reported.

This study observed that Black women with central centrifugal cicatricial alopecia had a higher prevalence of uterine leiomyomas compared to those with lichen planopilaris, suggesting a potential association between the conditions.

In this study, the application of human umbilical cord mesenchymal stem cell secretome significantly increased hair follicle count in fluconazole-induced alopecia in rats, although changes in epidermal thickness were not significant, suggesting a novel approach for hair restoration.

In this randomized clinical trial, the authors reported that adipose-derived stem cell constituent extract topical solution increased hair density and thickness in patients with androgenetic alopecia over 16 weeks compared to placebo.

This review covers the pathophysiology, diagnosis, and treatment of nonclassic congenital adrenal hyperplasia due to P450c21, but it reports no new clinical results.

This study observed that overexpression of the enzyme ODC in transgenic mice caused hair loss and skin changes similar to human papular atrichia, suggesting that ODC might be involved in a critical hair follicle function pathway.

This study found that diphencyprone showed a significant clinical response for treating alopecia areata, while tacrolimus was not effective.

In this study, 1'-S-1'-acetoxychavicol acetate (ACA) from Alpinia galanga showed potential in suppressing testosterone-induced hair loss by inhibiting Nox isozymes in a mouse model of androgenetic alopecia.

This systematic review and meta-analysis reported that deuruxolitinib is effective for hair regrowth and improving patient-reported outcomes in individuals with moderate to severe alopecia areata, but observed manageable treatment-emergent adverse events such as elevated creatinine kinase levels and headaches, particularly with higher doses.

This study found that hyperpigmentation following contact immunotherapy for severe alopecia areata may indicate poor treatment responsiveness and aligns with characteristics of pigmented contact dermatitis.

This study observed sustained hair regrowth in some patients with alopecia areata and improvement in vitiligo symptoms, indicating a potential role for dupilumab in treating these conditions, particularly when associated with atopic dermatitis.

This case series found that combining ablative fractional resurfacing and acoustic pressure ultrasound with triamcinolone treatment led to complete recovery in patients with areata alopecia.

This study found that mouse parents with uveitis may increase their offspring's susceptibility to experimental autoimmune uveitis, affecting immune processes and the severity of the condition.

In this meta-analysis, researchers found that oral dutasteride may stabilize or improve frontal fibrosing alopecia in patients, but results varied widely, and further controlled studies are needed to confirm its effectiveness as a treatment option.

This study reviewed therapies for alopecia areata and suggests that Janus kinase inhibitors, such as baricitinib and upadacitinib, show promise in treating both alopecia areata and associated immune-mediated inflammatory diseases.

This article discusses the ongoing care needs for individuals with 21-hydroxylase deficiency due to mutations in the CYP21A2 gene but does not present new clinical findings.

This report observed that a patient with alopecia areata, resistant to ritlecitinib, experienced significant recovery after 24 weeks of treatment with upadacitinib, highlighting its potential in treating ritlecitinib-resistant cases and suggesting personalized treatment strategies in managing alopecia areata.

This study explores the regulatory effects of ursolic acid on macrophage function and suggests potential for developing new anti-inflammatory and immunomodulatory drugs, though further research is needed for clinical applications.

This study reported two cases of alopecia areata where hair regrowth was achieved with zinc gluconate and sulfur amino acids after relapse post-PUVA cessation, suggesting potential zinc responsiveness in some patients.

This retrospective study concluded that PUVA treatment is generally ineffective for alopecia areata, with low effective success rates for partialis, totalis, and universalis types.

This article discusses topical and intralesional cidofovir use for SCC and suggests a successful outcome in one case, with no systemic toxicity observed so far.

This study reported that some pediatric patients with alopecia areata experienced hair regrowth with dupilumab treatment, particularly those with concomitant atopic dermatitis, suggesting dupilumab may be beneficial when traditional therapies fail.

Mini pulse corticosteroid therapy with oral dexamethasone is effective and has fewer side effects for treating extensive alopecia areata.

This review discussed the cutaneous manifestations of APECED, highlighting chronic mucocutaneous candidiasis, alopecia areata, and vitiligo, while emphasizing the importance of early detection and monitoring for accurate diagnosis and patient care in various populations.

This review discusses the evaluation, clinical presentation, and cutaneous manifestations of congenital adrenal hyperplasia, focusing on differential diagnosis challenges with polycystic ovary syndrome, and reports no new clinical findings.

In this study, the use of 5 alpha reductase inhibitors was associated with an increased risk of dementia during the first two years of treatment, but the risk was not significant with longer exposure.

Cortisone may help hair regrow by altering the local environment, with regrowth starting 3-4 weeks after treatment, but its use is not widely recommended.

This review discusses nitric oxide's physiological roles and the development of strategies for delivering it exogenously, without presenting new clinical results.